The Great Convergence: Cross-Modality Compensation Guide 2026
Standard biotech salary benchmarks no longer price radiopharmaceutical, ADC and in vivo gene therapy leadership correctly. This guide builds a cross-modality framework around an execution risk premium: a structured way to translate a single baseline market into a rate for a specific hub, company stage and modality, then close the hire.
What this report answers
- Why do standard biotech salary benchmarks under-price radiopharma, ADC and gene therapy leadership roles?
- How do you convert a Boston baseline into a defensible number for another hub or another funding stage?
- Which specific competencies justify a premium, and which absences should pull a candidate down a band?
- What does it actually cost to relocate senior manufacturing talent into a logistics hub?
- How should equity be structured differently at Series A against commercial stage?
- Which of these premiums are expected to soften or spike through 2027?
$300bn
of Big Pharma revenue the guide attributes to the approaching patent cliff - the pressure it argues has moved the market from paying for potential to paying for execution.
12-15%
the stabilised cost of capital the guide works from when explaining why theoretical platform value stopped clearing and why compensation is now priced against delivery risk.
What the analysis establishes
The calculator: baseline, hub, stage
The guide is built as a working tool rather than a survey. It sets one baseline market for each modality, then supplies adjustment factors for geography and for company stage, so a hiring manager can compose a rate for their own situation. It also explains why cost of living and cost of talent have separated, and which hubs that separation now favours.
Radiopharmaceuticals and the alpha premium
The radiopharma section is organised around what the guide calls the double lock: an NRC materials licence sitting on top of FDA GMP. It benchmarks technical operations and quality separately, sets out the three competencies that together justify the premium at each level, and names the licensed role without which a site cannot legally operate at all.
ADCs: containment and the oncology war
ADCs are benchmarked across two very different pressures. Clinical development competes for oncology leadership against everyone chasing the same solid tumour targets. Technical operations competes for people who can run a high-containment conjugation environment and manage tech transfer into external sites. The guide prices each separately and states where an ADC role sits relative to its radiopharma equivalent.
In vivo gene therapy and the scale-up gap
The pivot from ex vivo to in vivo shifts demand toward process engineering. The guide benchmarks vector operations, process development and analytical development, and identifies the specific scale-up experience that separates a genuinely scarce hire from the much larger population of cell therapy scientists competing for the same titles.
Sign-ons, equity and the relocation problem
Base salary opens the conversation and the cash bridge closes it. The guide benchmarks sign-on and relocation requirements by level for standard hubs against logistics hubs, where the gap is widest, and sets out how equity should shift from percentage ownership at Series A to dollar value at commercial stage.
Worked examples and the 2027 outlook
Two fully worked scenarios show the calculator applied end to end, from baseline through hub and risk adjustment to a complete offer. The closing section identifies which premiums the guide expects to soften as supply constraints ease, which hybrid roles it expects to appreciate, and which regional discount it expects to disappear.
How it was built
The guide deliberately avoids retrospective salary surveys, which the author argues lag the market by 12 to 18 months. The benchmarks are labelled as modelled composites, triangulated from three streams: compensation data from live executive search mandates, offers and counter-offers; public statutory filings and competitor job architectures; and adjustments for cross-modality inflation observed in high-velocity hiring corridors. Figures are stated as target market rates and planning ranges, not guaranteed outcomes, and the scope is United States senior leadership on a 2026 planning horizon.
Written for hiring managers, founders, boards and heads of talent scoping senior roles in radiopharmaceuticals, ADCs and in vivo gene therapy, and for investors validating a portfolio company's people budget.
Contents
- Executive Preface: The Brutal Calculus of Scale
- Methodology, Intelligence Architecture and Data Definitions
- The Calculator: Strategic Multipliers
- Modality I: Radiopharmaceuticals (The Alpha Premium)
- Modality II: Antibody-Drug Conjugates (The Containment Premium)
- Modality III: In Vivo CGT (The Scale-Up Premium)
- The Incentive Matrix: Sign-Ons, Equity and Retention
- Scenario Calculator: Worked Examples
- Future Proofing: The 2027 Outlook
Organisations referenced
BMS, Lilly, Lonza, MD Anderson, NorthStar, Nucleus, Pfizer, Seagen, WuXi
The full 13-page briefing is free. Tell us where to send it and it downloads immediately.